Replies to post #141121 on Biotech Values

[mcbio]

I think the people on this Scientific Advisory Board would know better than the people on the biotech values board whether this eyedrop has a chance to work.

Doesn't your line of reasoning here violate a key biotech newbie investing rule? ; )

[DewDiligence]

Squalamine eye drops for “multiple neovascular ophthalmic clinical indications each with sizable commercial markets”? I seriously doubt it.

I think the people on this Scientific Advisory Board would know better than the people on the biotech values board whether this eyedrop has a chance to work.

Having luminaries on a company’s SAB doesn’t make a bad drug better—see item #14 in #msg-71330113.

[DewDiligence]

OHRP adds more luminaries to its SAB (but, alas, this won’t make Squalamine a better drug):

http://finance.yahoo.com/news/ohr-pharmaceutical-announces-additions-ophthalmic-153000197.html

[DewDiligence]

OHRP reports more “positive” Squalamine data in rabbits:

http://finance.yahoo.com/news/ohr-pharmaceutical-announces-positive-preclinical-140000555.html

The stock closed up a penny.

[DewDiligence]

OPK does OHRP one better, licensing a topical formulation of Lucentis:

http://finance.yahoo.com/news/opko-health-announces-license-topically-143600032.html